Recent vaccine studies have attempted with varying degrees of success to turn immune infiltrate poor microenvironments into tumor microenvironments suitable for checkpoint blockade including the use of adjuvants such as Toll-like receptor ligands and STING agonists [68,69]. This evidence concerns the gene STING1 and neoplasm.